Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05602935
PHASE2

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Sponsor: The Second Affiliated Hospital of Fujian Medical University

View on ClinicalTrials.gov

Summary

This is a single-arm, phase II study of camrelizumab combined with SOX regimen in subjects with resectable locally advanced gastric cancer. The patients will receive camrelizumab ,S-1 and oxaliplatin given every 3 weeks for 3 cycles as neoadjuvant therapy. After the surgery, adjuvant therapy which includes camrelizumab and SOX regimen will begin.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

29

Start Date

2020-09-16

Completion Date

2026-12-30

Last Updated

2023-09-28

Healthy Volunteers

No

Interventions

DRUG

Camrelizumab

200mg, intravenously, d1

DRUG

SOX

SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)

PROCEDURE

Surgery

Surgery

Locations (1)

The Second Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China